NovaTears® Eye Drops Observational Study NT-002

NCT02356341 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2016-03-09

No results posted yet for this study

Summary

This observational study is intended to collect outcome data from a cohort of 90 patients suffering from symptoms of dry eye disease due to meibomian gland dysfunction who are treated with the medical device NovaTears® eye drops for a duration of 6 to 8 weeks.

Conditions

  • Dry Eye Syndromes

Interventions

DEVICE

NovaTears® Eye Drops

Topical eye drops for lubrication of the ocular surface

Sponsors & Collaborators

  • Novaliq GmbH

    lead INDUSTRY

Principal Investigators

  • Novaliq GmbH · Novaliq GmbH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02356341 on ClinicalTrials.gov